CRNX - Crinetics rated Outperform at Oppenheimer on upcoming Phase 3 data
2023-08-31 09:42:53 ET
More on Crinetics
- Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly
- Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO
- Crinetics says FDA didn’t clear Phase 2 study request for hyperinsulinism drug
- Crinetics hormone CRN04894 therapy shows promise in early-stage study
- Crinetics stock gains on hyperinsulinism candidate's trial data; JMP raises PT
- Crinetics shows dose-dependent effect of hyperinsulinism candidate in early trial
- Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals
- Earnings data for Crinetics Pharmaceuticals
For further details see:
Crinetics rated Outperform at Oppenheimer on upcoming Phase 3 data